Scientists test approved ALS drug on wider patient group
NCT ID NCT07294144
Summary
This study is testing whether tofersen, a drug already approved for a specific genetic form of ALS, is safe and can lower a key disease marker in people with ALS who do not have that specific gene mutation. About 30 adults with early-stage ALS will receive the drug via spinal injections over 24 weeks. Researchers will measure a protein in the blood and spinal fluid linked to nerve damage, monitor safety, and track symptoms and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University ALS Center
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.